Webinar: Re-Writing the Genome

March 12, 2018 | Posted by Team in Webinar |

Combining Gene Editing and iPSC Technologies
for Preclinical Discovery and Translational Research

Watch our webinar on-demand to hear Ruby Chen-Tsai, Ph.D., CSO of Applied StemCell, discuss how her team is using genome engineering and iPSC technologies to advance disease modeling, lead compound discovery, and bioproduction.


You will learn about:

  • Using genome engineering technologies for the generation of preclinical research models
  • How genome editing technologies can be applied to the development of cell and gene therapies
  • Application of gene editing to bioproduction
  • CRISPR-mediated gene editing for the development of nucleic acid reference standards

About Our Speaker

Ruby Yanru Chen-Tsai, Ph.D. has worked on the development and modification of stem cells and pre-clinical models for over 25 years. Prior to Applied StemCell, Dr. Chen-Tsai was at Stanford University, where she served as Director of the Transgenic Research Center and Associate Director of the Stanford Cancer Institute. Dr. Chen-Tsai is a co-inventor of the TARGATT™ integrase technology and the “DICE” platform for site-specific gene insertion. Her current research focuses on pre-clinical model development, as well as gene- and stem cell-based therapies using genome editing technologies including CRISPR/Cas9 and TARGATT™ integrase.

In vivo Phenotypic Screening: Melior Discovery

August 19, 2017 | Posted by Team in Provider Spotlight |

By Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.com

Melior Logo

Phenotypic Screening Pioneer Launches Novel Analgesia Panel

In this Provider Innovation Profile, we’re proud to feature Melior Discovery, a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning.

Melior’s platform evaluates compounds through up to 40 different animal models representing 14 broad therapeutic areas, potentially uncovering therapeutic efficacy that might be undetected using traditional assessments.

Recently, Melior made the news with its novel opioidTRACE® Analgesic Profiling Platform. Given the need to develop low-abuse analgesics to address the opioid crisis, Melior has configured an in vivo platform aimed at specifically profiling opioid therapeutics and related analgesics.

The opioidTRACE® platform addresses the multiple features characteristic of opioids, including rodent models that evaluate acute analgesia, chronic analgesia, respiratory depression, GI mobility, and abuse liability. In addition to opioid testing, Melior has a wide array of animal models of analgesia ranging models of acute pain to chronic neuropathy models. 

[click to view larger view of opioidTRACE® animal models]Opioid Trace In Vivo Models

Backed by Expertise in In Vivo Screening

Melior’s new panel is just the latest demonstration of the team’s unique know-how in applying “production-mode” methods for in vivo screening across multiple therapeutic areas. Its proprietary theraTRACE® platform enables rapid and cost-effective identification of new therapeutic potential by systematically screening candidates in a diverse array of validated in vivo disease models.

Fibrosis is another disease area for which Melior’s panels have exemplified the utility of in vivo  phenotypic screening. Melior has validated models of liver and lung fibrosis; download the validation data for these models from the Resources section of Melior’s Science Exchange storefront.

Why Requesters are Choosing Melior for In vivo Studies

Melior’s capability directly translates to efficiencies combined with high levels of quality for their clients. Positive ratings and testimonials illustrate the benefits that attract repeat business for Melior:

  • High reproducibility and predictive power of in vivo methodologies, models, and assays assuring high quality of data
  • Lower overall costs resulting from the availability of highly cost effective preclinical services from Melior
  • Rapid responses to requests for service and quick turnaround times for preclinical studies
  • Ability to rapidly customize, design, and modify models in response to requests for specialized in vivo services or changes in protocols or unexpected results at any stage of the study

Dr. Sridharan Rajamani, Senior Research Scientist at Gilead Sciences, said that his team chose Melior Discovery because they were responsive and cost effective.  “We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail,” said Dr. Rajamani. “Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.”  

Interested in working with Melior Discovery? Request a quote to start the discussion.

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com